Jefferies Sticks to Its Buy Rating for CytomX Therapeutics Inc

By Jason Carr

In a report released yesterday, Biren Amin from Jefferies reiterated a Buy rating on CytomX Therapeutics Inc (NASDAQ: CTMX), with a price target of $25. The company’s shares closed yesterday at $13.93.

According to TipRanks.com, Amin is a 3-star analyst with an average return of 2.4% and a 47.3% success rate. Amin covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Stemline Therapeutics Inc, and Lion Biotechnologies Inc.

CytomX Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $27.

Based on CytomX Therapeutics Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $11.65 million and GAAP net loss of $8.26 million. In comparison, last year the company earned revenue of $2.22 million and had a GAAP net loss of $16.03 million.

Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CTMX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytomX Therapeutics, Inc. operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer. The company was founded in September, 2010 and is headquartered in South San Francisco, CA.